This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite. Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
Call 1-800-966-2244 to find out how we can help receive compensation for you and your family or fill out this short form to find a mesothelioma lawyer in your area.
- Start Date: January 2007
- Primary Completion Date:
- Completion Date:
- Last Updated Date: May 22, 2009
Disease Characteristics
- Exposure to vermiculite or asbestos insulation
- Symptomatic or nonsymptomatic exposure-related disease
- Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)
Patient Characteristics
- Not specified
Prior Concurrent Therapy
- Not specified
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897247.
Information on How You Can Participate In This Clinical Trial
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan 48201
313-576-9363
Sinai-Grace Hospital
Detroit, Michigan 48235
Contact: Naimei Tang 313-966-3300
Find More Information on
- Detecting Abnormal Cells in Patients Surgery for Lung Cancer
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
- Pemetrexed Observation in Treating Patients With Malignant Pleural Mesothelioma
- Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
- Study of Patients With Malignant Pleural Mesothelioma Cancers
Call 1-800-966-2244 to find out how we can help receive compensation for you and your family or fill out this short form to find a mesothelioma lawyer in your area.
